Agilent Technologies Inc. (A)

NYSE · Healthcare

Latest Move · 2026-02-26

-4.90%
Margin pressure and slight earnings miss overshadow raised guidance after Q1 report

Agilent Technologies reported fiscal first-quarter earnings on Wednesday that fell short of Wall Street expectations. The company posted adjusted earnings per share of $1.36, missing the average analyst estimate of $1.37. Revenue of $1.8 billion met Street forecasts. The company raised its full-year adjusted earnings guidance to $5.90 to $6.04 per share and raised revenue guidance to $7.3 billion to $7.5 billion. First-quarter results were pressured by tariffs that reduced non-GAAP gross margin by 100 basis points and a winter storm that caused approximately $10 million in shipping disruptions from the Memphis logistics hub. Management stated the majority of storm-related revenue was recovered in early February. The stock declined 4.9% following the earnings announcement.

Read full analysis

Frequently Asked Questions

Why did Agilent Technologies Inc. stock move today?

Agilent Technologies reported fiscal first-quarter earnings on Wednesday that fell short of Wall Street expectations. The company posted adjusted earnings per share of $1.36, missing the average analyst estimate of $1.37. Revenue of $1.8 billion met Street forecasts. The company raised its full-year adjusted earnings guidance to $5.90 to $6.04 per share and raised revenue guidance to $7.3 billion to $7.5 billion. First-quarter results were pressured by tariffs that reduced non-GAAP gross margin by 100 basis points and a winter storm that caused approximately $10 million in shipping disruptions from the Memphis logistics hub. Management stated the majority of storm-related revenue was recovered in early February. The stock declined 4.9% following the earnings announcement.

What does Agilent Technologies Inc. do?

Agilent Technologies is a scientific instruments and diagnostics company based in Santa Clara, California, serving pharmaceutical, chemical, and applied-science end markets with analytical equipment, consumables, and services. The company generates roughly $7.3–$7.5 billion in annual revenue and has been benefiting from GLP-1 drug development demand and replacement cycles. Today's selloff centers on whether tariff-related margin pressure will erode profitability even as top-line growth remains intact.

Healthcare Stocks

AI-generated analysis · Not financial advice · Always do your own research
Disclaimer & Terms · Privacy Policy